{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-116720","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2026-10-19T11:12:47+00:00","discovered_at":"2026-10-19T11:15:00.345591+00:00","generated_at":"2026-10-19T11:15:09.500592+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Marker Therapeutics wins $2.6M FDA orphan grant for MT-601 pancreatic cancer trial","bullets":["FDA awarded Marker Therapeutics $2.6 million under its Orphan Products Clinical Trials grants program to support a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer.","FDA received 66 applications for the FY2026 orphan products program and selected six, including Marker's MT-601 project.","Marker plans to initiate the company-sponsored pancreatic cancer study in Q1 2027, using expanded antigen targeting, higher T-cell doses, and lymphodepletion.","Prior Baylor Phase 1/2 data in Nature Medicine showed 84.6% disease control, 7.5-month median duration of response, and 14.1-month median overall survival."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-116720","json":"https://secwatch.observer/filing/0001104659-26-116720.json","markdown":"https://secwatch.observer/filing/0001104659-26-116720.md","text":"https://secwatch.observer/filing/0001104659-26-116720.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926116720/0001104659-26-116720-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926116720/tm2627740d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-19T11:15:09.500592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}